SS
NKTR icon

SBI Securities’s Nektar Therapeutics NKTR Stock Holding History

SBI Securities’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192K Buy
2,750
+2,609
+1,850% +$191K ﹤0.01% 676
2026
Q1 		$10.1K Sell
141
-5
-3% -$285 ﹤0.01% 1712
2025
Q4 		$6.17K Sell
146
-10
-6% -$560 ﹤0.01% 1937
2025
Q3 		$8.88K Sell
156
-4
-3% -$132 ﹤0.01% 1821
2025
Q2 		$4.13K Buy
160
+137
+596% +$1.54K ﹤0.01% 2079
2025
Q1 		$238 Buy
23
+22
+2,200% +$287 ﹤0.01% 3155
2024
Q4 		$13 Buy
+1
New +$18 ﹤0.01% 3898

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's NKTR Position: Q2 2026 in Review

SBI Securities increased its Nektar Therapeutics (NKTR) stake by 1,850% in Q2 2026, buying an estimated $191K and bringing the position to 2,750 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #676.

SBI Securities first reported a position in NKTR in Q4 2024 and has held it in 7 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • SBI Securities held 2,750 shares of Nektar Therapeutics worth $192K as of Q2 2026.
  • SBI Securities bought 2,609 Nektar Therapeutics shares in Q2 2026, an estimated $191K.
  • Nektar Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #676 holding.
  • SBI Securities first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.